Display Settings:

Format

Send to:

Choose Destination
J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Author information

  • 1Duke Human Vaccine Institute, Durham, North Carolina, USA. mattia.bonsignori@duke.edu

Abstract

Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.

PMID:
22301150
[PubMed - indexed for MEDLINE]
PMCID:
PMC3318651
Free PMC Article

Images from this publication.See all images (3)Free text

Fig 1
Fig 2
Fig 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk